STOCK TITAN
  1. Home
  2. News
  3. SRDX

Surmodics, Inc. - SRDX STOCK NEWS

Welcome to our dedicated news page for Surmodics (Ticker: SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Surmodics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Surmodics's position in the market.

News
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
Rhea-AI Summary
Surmodics, Inc. (Nasdaq: SRDX) will report its second quarter of fiscal 2024 financial results on May 1, with a live webcast and conference call to discuss the achievements. The earnings call will be at 7:00 am (CT) and can be accessed through the Company's website. An audio replay will be available until May 15.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences earnings
-
News
Surmodics to Participate in Upcoming Investor Conferences in March and April
Rhea-AI Summary
Surmodics, Inc. (SRDX) will participate in investor conferences, including the 34th Annual Oppenheimer Healthcare Conference and the 23rd Annual Needham Healthcare Conference. Management will present and participate in fireside chats at these events, offering insights into the company's medical device and in vitro diagnostic technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences
-
News
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
Rhea-AI Summary
Surmodics, Inc. (SRDX) reported a 23% increase in total revenue for the first quarter of fiscal 2024, reaching $30.6 million. The GAAP net loss decreased to $(0.8) million from $(7.8) million in the prior-year period. Adjusted EBITDA was $3.9 million, compared to a loss of $(3.3) million in the prior-year period. The company raised its fiscal 2024 total revenue and EPS guidance, expecting a growth of 10% or higher for the full year. Surmodics also announced significant operational progress with respect to its strategic objectives for fiscal 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.9%
Tags
earnings
News
Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee
Rhea-AI Summary
Surmodics, Inc. (SRDX) announces the successful early clinical use of the Pounce LP Thrombectomy System, a low-profile device designed for efficient clot removal in peripheral arteries ranging from 2 mm to 4 mm. The system received FDA clearance in June 2023 and is currently in limited market evaluation, with full commercial launch planned following completion of the LME. The Pounce LP System complements the original Pounce Thrombectomy System, introduced in 2021, and is indicated for use in vessels below the knee. Early clinical use has shown positive results, with vascular surgeons praising the device's effectiveness in treating chronic thrombus in complex lesions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
-
News
Surmodics to Host Virtual Annual Meeting of Shareholders
Rhea-AI Summary
Surmodics, Inc. (SRDX) will hold its Annual Meeting of Shareholders on February 8, 4 p.m. CT. The virtual meeting will be led by Chair of the Board, Sue Knight, and President/CEO Gary Maharaj will provide business updates. To attend, visit www.virtualshareholdermeeting.com/SRDX24. A webcast replay will be available until February 9, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences
-
News
Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1
Rhea-AI Summary
Surmodics, Inc. (SRDX) will release its first quarter fiscal year 2024 financial results on February 1, followed by a conference call and webcast to discuss the results and accomplishments. The live webcast will be accessible through the company's website, while the teleconference can be accessed by dialing a provided number. An audio replay of the conference call will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences earnings
News
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announces promising 24-month data from the SWING Trial on the Sundance™ Sirolimus Drug-Coated Balloon (DCB) for treating occlusive disease of the infrapopliteal arteries. The trial achieved its primary safety and efficacy endpoints, showcasing a 71.4% primary patency rate at 24 months in the per protocol analysis population. The results were presented at the 50th annual VEITH Symposium in New York, New York, demonstrating an excellent safety profile with sustained positive outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
-
News
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced the 36-month data from its TRANSCEND clinical trial, presenting the safety and efficacy of the SurVeil drug coated balloon (DCB) compared to the IN.PACT Admiral DCB for treating superficial femoral and proximal popliteal artery lesions. The primary efficacy and safety endpoints showed comparable outcomes, demonstrating the non-inferiority of the SurVeil DCB to the IN.PACT Admiral DCB. Dr. Peter A. Schneider presented the data at the 50th Annual VEITH Symposium in New York, New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
-
News
Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28
Rhea-AI Summary
Surmodics, Inc. (SRDX) to Participate in 35th Annual Piper Sandler Healthcare Conference. The company's management will present at the conference on November 28, 2023, and a live webcast of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
conferences
News
Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance
Rhea-AI Summary
SRDX: Surmodics Reports Strong Financial Results and Fiscal 2024 Guidance, Announces New Product Launches and Clinical Trial Data
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.36%
Tags
earnings
Stock SRDX logo
Surmodics, Inc.

Nasdaq:SRDX

SRDX Rankings

#3224 Ranked by Market Cap
#3099 Ranked by Stock Gains
N/A Ranked by Dividends

SRDX Stock Data

384.37M
10.61M
3.75%
91.43%
3.14%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Eden Prairie

About SRDX

surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.